Insights

Why Goldman Sachs sees 13% upside for the ResMed share price

Here’s why ResMed shares could be in the buy zone…
The post Why Goldman Sachs sees 13% upside for the ResMed share price appeared first on The Motley Fool Australia. –

The ResMed Inc (ASX: RMD) share price was on form on Friday.

The sleep treatment focused medical device company’s shares rose almost 3% to $30.45.

Can the ResMed share price keep rising?

The good news for investors is that one leading broker still sees plenty of room for the ResMed share price to keep rising.

According to a recent note out of Goldman Sachs, its analysts have a buy rating and $34.40 price target on its shares.

This implies potential upside of 13% for investors over the next 12 months.

What did the broker say?

Goldman notes that ResMed has announced plans to acquire Medifox Dan for US$1 billion.

It is an out-of-hospital software provider based in Germany which generated revenue of US$83 million and EBITDA of US$35 million in calendar year 2021.

Goldman appeared pleased with the deal. It commented:

The acquisition goes some way to answering a long-held question the market has had around when/how the company would attempt to replicate its SaaS strategy outside of the US market.

What else is the broker saying?

Its analysts also highlight that the ResMed share price has been underperforming in FY 2022 due to concerns over supply chain headwinds. This has stopped the company from taking full advantage of a major product recall from rival Philips.

However, Goldman feels the market is overreacting and expects elevated demand to stick around long enough for ResMed to benefit. It also sees a backlog of patients waiting to be diagnosed as a potential upside risk to estimates.

Its analysts explained:

We believe the elevation in demand could persist beyond the time it takes for component shortages to improve (via both external and internal factors) and, as such, the YTD underperformance of the shares may be over-capitalising relatively short-term headwinds.

We believe the backlog of new patients may add upside to our estimates if there is a material realisation of incremental devices/masks sales to new patients in FY23/24 (supply chain pressures permitting). The return of PHIA to the market may actually help in this regard, as the company supplies critical diagnosis equipment.

The post Why Goldman Sachs sees 13% upside for the ResMed share price appeared first on The Motley Fool Australia.

Should you invest $1,000 in Resmed Inc. right now?

Before you consider Resmed Inc., you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Resmed Inc. wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of June 1 2022

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

This is what I’d do with these 3 battered ASX shares: fund manager
Goldman names 2 ASX healthcare shares to buy
2 ASX shares to benefit from strong US dollar: expert
Why I would invest $10,000 in these 3 ASX shares
ASX 200 midday update: ResMed’s US$1bn acquisition, tech shares continue to sink

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info